ACADIA PHARMACEUTICALS INCACAD财报
Nasdaq · pharmaceutical industry
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
主要股东
| 股东 | 持股比例 | 股数 | 变动 | 截至 |
|---|---|---|---|---|
| Baker Bros. Advisors LP | 26.50% | 43.1M | — | 2023-05-24 |
| RTW Investments, LP | 8.30% | 13.7M | ▲ +1.40pp | 2024-11-14 |
| The Vanguard Group | 8.16% | 13.4M | — | 2024-02-13 |
| BlackRock, Inc. | 6.90% | 11.4M | — | 2024-01-26 |
| FMR LLC | 3.21% | 5.3M | — | 2024-02-09 |
内部人交易
Net 90d: −$852.7K · buys $0 / sells $852.7K时间范围:
类型:
身份:
| 内部人 | 身份 | 类型 | ||||
|---|---|---|---|---|---|---|
| 2026-04-07 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell (open market) | 2.7K | $22.20 | $60.1K |
| 2026-04-07 | James Kihara | PRINCIPAL ACCOUNTING OFFICER | Sell (open market) | 1.0K | $22.20 | $22.9K |
| 2026-04-05 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Option exercise | 5.3K | — | — |
| 2026-04-05 | James Kihara | PRINCIPAL ACCOUNTING OFFICER | Option exercise | 2.0K | — | — |
| 2026-03-26 | James Kihara | PRINCIPAL ACCOUNTING OFFICER | Sell (open market) | 1.1K | $21.65 | $23.8K |
| 2026-03-26 | James Kihara | PRINCIPAL ACCOUNTING OFFICER | Sell (open market) | 12 | $21.73 | $261 |
| 2026-03-26 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell (open market) | 3.2K | $21.65 | $68.7K |
| 2026-03-26 | Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER | Sell (open market) | 37 | $21.72 | $804 |
| 2026-03-25 | Thompson Elizabeth H.Z. | EVP, Head of Research & Dev | Sell (open market) | 3.4K | $21.47 | $73.7K |
| 2026-03-25 | Owen Adams Catherine | Chief Executive Officer | Sell (open market) | 11.6K | $21.47 | $249.9K |
1–10 of 22
第 1 页 / 共 3 页